ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) and NeuroPace (NASDAQ:NPCE – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.
Profitability
This table compares ENDRA Life Sciences and NeuroPace’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ENDRA Life Sciences | N/A | -433.64% | -204.58% |
| NeuroPace | -21.67% | -108.20% | -18.50% |
Analyst Recommendations
This is a breakdown of current ratings and price targets for ENDRA Life Sciences and NeuroPace, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ENDRA Life Sciences | 1 | 0 | 1 | 0 | 2.00 |
| NeuroPace | 1 | 1 | 4 | 2 | 2.88 |
Valuation & Earnings
This table compares ENDRA Life Sciences and NeuroPace”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ENDRA Life Sciences | N/A | N/A | -$7.03 million | ($8.15) | -0.58 |
| NeuroPace | $99.53 million | 5.35 | -$21.47 million | ($0.65) | -24.05 |
ENDRA Life Sciences has higher earnings, but lower revenue than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
1.2% of ENDRA Life Sciences shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 10.0% of ENDRA Life Sciences shares are owned by insiders. Comparatively, 20.5% of NeuroPace shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
ENDRA Life Sciences has a beta of -0.04, meaning that its share price is 104% less volatile than the S&P 500. Comparatively, NeuroPace has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500.
Summary
NeuroPace beats ENDRA Life Sciences on 10 of the 14 factors compared between the two stocks.
About ENDRA Life Sciences
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
About NeuroPace
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.jpg){kind=logo}
